{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 28,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to illustrate the central strategy of 'Targeting Cancer + Immunomodulation' supported by five distinct therapeutic platforms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/7",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.85
      },
      "kind": "callout",
      "text": "Potential for multiple blockbuster opportunities with powerful combinations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5b4065a-dca4-4857-936d-813df1f0441b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.36,
        "x": 0.32,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Targeting Cancer + Immunomodulation",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67638dc5-29f2-405f-876b-f5ed71243990",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.03,
        "y": 0.24
      },
      "kind": "list",
      "text": "mRNA Cancer Vaccines: Randomized Phase 2 trial starts for FixVac and iNEST in multiple solid tumors expected in 2H 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "228d33f3-ce3b-46e4-81dc-4b7545825e7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.03,
        "y": 0.52
      },
      "kind": "list",
      "text": "Cell Therapies: Phase 1/2 trial start for CARVac planned in 2H 2020; Filed IND for Phase 1 trial of ex-vivo neoantigen T cell therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "433a6535-a6c0-4085-b88f-070854c8d3f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.69,
        "y": 0.24
      },
      "kind": "list",
      "text": "Next Generation Immunomodulators: First Phase 1/2 data expected for PD-L1 x 4-1BB antibody in 2H 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55c2d495-906d-44a1-b970-83b32d052ed7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.28,
        "y": 0.68
      },
      "kind": "list",
      "text": "Antibodies: Ongoing Phase 1/2 trial for CA19-9 antibody in pancreatic cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a71a108-ca0d-4b07-af89-14cd65a13d58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.51,
        "y": 0.68
      },
      "kind": "list",
      "text": "Small Molecule Immunomodulators: First-in-human Phase 1/2 trial for TLR7 agonist initiated in early July 2020",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a00da01e-9888-4200-bcac-914919d93c3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.72,
        "y": 0.52
      },
      "kind": "list",
      "text": "Engineered Cytokines: First Phase 1/2 data from intratumoral mRNA in 2H 2020; Ribocytokines to enter the clinic in 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f507a789-5da0-4fed-9974-835e303750ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Broad progress in executing our multi-platform IO strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30641534-1a46-48b4-8161-cbcff63b260f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "918d72d8-8659-4fb7-beab-aa58198676fc",
      "evidence": "list/bullet: Cell Therapies: Phase 1/2 trial start for CARVac planned in 2H 2020; Filed IND for Phase 1 trial of ex-vivo neoantigen T cell therapy",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "94fc86dd-d13a-4c0c-8093-0b38108a5b0c",
      "evidence": "Central hub 'Targeting Cancer + Immunomodulation' with spokes to therapeutic platforms",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "d225e240-012c-43ec-9ad8-8849e22c98f8",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights the potential for multiple blockbuster opportunities and the need for innovative solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "558811c9-2680-40b0-851c-c38adb20b5e2",
      "evidence": "The presentation highlights the company's focus on immunotherapy and COVID-19 vaccine development",
      "position": 0,
      "objective": "What are the key areas of focus for BioNTech's pipeline?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}